Abstract
The use of intravenous verapamil for tachyarrhythmia in infants is widely considered contraindicated due to the perceived risk of hemodynamic collapse after administration. This article reviews the relatively limited evidence that led to this well-known contraindication and highlights the interesting process by which medical practice may evolve in the absence of persuasive science.
MeSH terms
-
Calcium Channel Blockers / adverse effects
-
Calcium Channel Blockers / therapeutic use
-
Global Health
-
Health Knowledge, Attitudes, Practice*
-
Heart Failure / chemically induced*
-
Heart Failure / epidemiology
-
Heart Failure / physiopathology
-
Hemodynamics / drug effects*
-
Humans
-
Incidence
-
Infant
-
Risk Factors
-
Tachycardia / drug therapy*
-
Tachycardia / physiopathology
-
Verapamil / adverse effects*
-
Verapamil / therapeutic use
Substances
-
Calcium Channel Blockers
-
Verapamil